A traditional medical school curriculum does not formally prepare physicians to participate in evaluation of safety and effectiveness after medications enter the market. This article provides examples where ultrasound has unrealized potential as a noninvasive tool for longitudinal assessment of drug safety and effectiveness in the real-world. The examples are intended to sensitize medical schools and medical students to opportunities for physicians to advance therapeutic evaluation of drugs as they are used for approved and unapproved indications in actual practice.
often poorly described in terms of patient characteristics and disease status. No denominator of drug use is available to judge the frequency of the cases, which should be the numerator, so estimates of the rates of harm are unobtainable. The inadequacies of a voluntary adverse drug reaction reporting system are universally recognized, and are underscored by widely publicized withdrawals of popular drugs because of fatal or near-fatal effects that were not detected during clinical trials prior to marketing. 1 The Food and Drug Administration Amendments Act (FDAAA) of 2007 intends to strengthen the FDA's role and improve the system for assuring the safe and appropriate use of drugs after they are marketed. 6 Still, the main mechanism for detecting adverse drug effects and to determine whether the efficacy demonstrated in clinical trials will similarly affect health outcomes in actual practice hinges on spontaneous voluntary reporting by physicians. Imagine postgraduate surveillance of medical schools, comparing graduates of a school that actively prepares students to become engaged in pharmacosurveillance to the general run of schools that are passive. Might formal medical educational efforts make a substantial difference in the rate and extent that drug safety and effectiveness is evaluated in clinical practice? Can medical education drive the capacity Efficacy describes how a drug performs under optimum clinical trial conditions, and is taken to estimate effectiveness in actual practice. Similar to most industrialized countries, the system for drug evaluation in the United States consists of premarketing efficacy trials of relatively short duration, that tend to include about 1,500 to 4,000 highly selected, homogeneously uncomplicated cooperative patients closely monitored by highly specialized physicians. 1 Efficacy trials address a few highly specific, most often surrogate outcomes chosen by the manufacturer to satisfy regulatory requirements for authorization to market the drug. 2 Not all actual or potential risks will be known at the time a drug enters clinical use. There may be subsets of patients for whom the risk is greater than it appears to be for the target population as a whole. 3 Preclinical trials tend to over-estimate clinical benefit and under-estimate potential harm to the broader population of patients receiving the drug in actual clinical practice. Monitoring programs for the period after a medication enters the market have traditionally focused on pharmacovigilance, which is directed at identifying unanticipated or severe harm. 1 Pharmacosurveilance refers to monitoring populations for benefit and harm related to medications used in the context of real world clinical practice. 4 For several decades, the mechanism to evaluate the real world safety and effectiveness of medications after they enter the market has relied substantially on ad hoc and motivation of future physicians to play a more active role in assessing whether the treatments they prescribe are the safest and most effective therapeutic choices for their patients? Multisite, international collaborations among clinicians and clinical groups are well-established for research into specific conditions such as cancer and diabetes. One of the best examples is the Children's Oncology Group (COG), an organization that has treated and monitored children with cancer for more than 40 years. Over 200 medical institutions in the US and many in Canada participate in the group. Each institution has a multidisciplinary team of clinicians for diagnosis, treatment, and surveillance of all principal cancers of infants, children, and adolescents-over 40,000 patients. 2 Could such an initiative be undertaken in gynecology? Considering the advancements that have been made in the diagnostic and research use of ultrasound, gynecology has a remarkable tool for pharmacosurveillence: noninvasive, widely accessible, known to provide usefully detailed resolution of structure and function in up to four dimensions, and versatile in the scope of its application without directly influencing the condition it is being used to assess. This article is not a comprehensive overview. The aim is to provide insight by way of examples of how future physicians could apply ultrasound to strengthen the evaluation of drug therapy for gynecological disorders.
One of the most useful examples is the application of color Doppler ultrasound to assess responses to medical treatment for uterine leiomyomata. Definitive treatment of leiomyomata is surgical, but drug therapies have a role as adjuncts and possibly as a monitored alternative. 6 The rate and magnitude of response to gonadotropin-releasing hormone super agonists can purportedly range from no detectable change up to a 90% reduction in size over a period of 8-12 weeks. 7 Noting that larger submucous and subserous leiomyomata are particularly responsive, variation in response is hypothesized to depend on differences in size, location, vascularity, impedence to blood flow 8 ( Figs   1 to 3 ). These parameters could provide an index to stratify candidates for medical management, for vaginal, laparoscopic or abdominal myomectomy/hysterectomy. It could also evolve into a validated standard for comparing therapeutic efficiencies of different classes of drugs, including in particular, GnRH super agonists in relation to the newer GnRH antagonists, mifepristone, danazol, longacting progestins, aromatase inhibitors or somatostatin A modern combined hormonal contraceptive containing ethinyl estradiol 20 gm and levonorgestrel 100 gm equates to 1.2% of the recommended dose of Enovid ® , the first combined oral hormonal contraceptive marketed in the United States in the mid-60s. It took about two decades in the postmarketing period to establish that such a markedly lower dose was no less effective while providing a greater margin of safety and improved toleration. 10 Currently, almost all new drug products that are approved for noncyclic use to prevent pregnancy or manage chronic gynecologic conditions are being prescribed for periods longer than they were evaluated in controlled trials. Lybrel being first on the market in May 2007, the primary focus is on venous thrombotic events, but there is still uncertainty about the safety of maintaining the decidua indefinitely. 11 Ultrasound is widely available to monitor and report effectiveness and complications in women for whom this product is prescribed on an extended basis for any indication, including labeled use for contraception, or off-label use for anovulatory uterine bleeding, polycystic ovary syndrome or endometriosis. It would be of interest to opportunistically correlate ultrasound data with endometrial biopsies and biomarkers. Despite hopeful preliminary reports, 12-15 the protective effect of pituitary-ovarian down-regulation with GnRH analogs such as leuprolide and assumptions that benefits exceed risks remain unproven. 16 In relation to the agedependent decline in primordial follicle reserves spanning the continual process of atresia, the older the postmenarchal patient the higher the probability of ovarian failure. Given the high-rate of premature ovarian failure in a patient approaching 30 years of age, the potential treatment benefits are likely to be lower, but perhaps more critical if she wishes to conceive. For a patient who is truly intent on conceiving after entering a disease-free period, serious consideration would be given toward a chemotherapeutic regimen that is least deleterious to the ovaries, one that would minimize exposure to cyclophosphamide and platinum-containing agents, for example. Due to possible toxicity of chemotherapy on growing oocytes, a 6-12 month washout period has been suggested prior to attempts to conceive. However, the patient's intention to conceive as early in the disease-free period as possible may be fundamental to the potential success of pituitary-ovarian down-regulation with GnRH. Ultrasound could be used to estimate pretreatment follicle reserve, evidence of suppression and resumption of follicular growth, although biopsy is required to ascertain the ultrastructural integrity of primordial follicles 17 ( Figs 6 to 8).
The advancements achieved particularly in the gynecologic and obstetrical application of ultrasound provides unique capacity for physicians who are sensitized and educationally prepared to organize and contribute to the ongoing evaluation of therapies as they are used in actual clinical practice. 
